Genexis Biotech, a bio-manufacturing startup, has raised INR 4 crore in seed funding. The round was led by GVFL, with support from Benzai10.
The funds will be used to expand bioreactor capacity, set up downstream processing infrastructure, launch new recombinant proteins and enzymes, and boost compliance, sales and distribution capabilities.
“Genexis is solving a critical gap in India’s biotech value chain by enabling high-quality, animal-origin-free protein production at scale. The company’s R&D strength, infrastructure, and early traction position it well to serve a growing demand across biopharma, food-tech, and life sciences. We are pleased to support Genexis in this transformative journey, said Mihir Joshi, Managing Director of GVFL.
Vipul Kumar, Director at Genexis Biotech, said, “At Genexis Biotech, we are building India’s deep-tech backbone for animal-origin-free protein production. The seed round marks a key milestone in our journey and will accelerate our path to scale, enabling sustainable innovation across healthcare, food and bio-industrial sectors.”
In the last year, Genexis has grown its product range to include recombinant growth factors, peptidases, and cell culture reagents. These are important ingredients used in biotech and pharmaceutical research.
The company has also formed strategic partnerships with pharma companies, biotech startups, and research labs. Its certified Class 10,000 manufacturing facility is now up and running, and a new GMP-compliant unit is also being developed.
In its next phase of growth, Genexis Biotech plans to expand into the regulated biotech export market. The company also aims to build strategic partnerships with CDMOs (Contract Development and Manufacturing Organizations), academic institutions, and biopharma companies. Additionally, it is working on developing encapsulated growth factor formulations for use in the cosmetics industry.
Vadodara-based Genexis Biotech was founded in 2019. It is a cutting-edge bio-manufacturing company producing high-quality, animal-free proteins through recombinant technology and precision fermentation.
Backed by strong in-house R&D and ISO-compliant facilities, it caters to industries such as biopharma, regenerative medicine, cell culture media, and cultivated meat. Genexis is committed to making biomolecules more accessible, ethical, and scalable—driving a greener, self-sufficient biotech future.
Read more- AI Marketing Startup Hall Raises $2M Pre-Seed to Redefine SEO in the AI Era
